Oryzon Secures Vafidemstat Patent Allowances in Four Countries
Oryzon Genomics received decisions to grant vafidemstat patents in four markets, expanding protection for psychiatric and neurodevelopmental uses. South Korean and Philippine allowances cover non-aggressive borderline personality disorder symptoms, with protection expected through at least 2040, excluding potential ext